|
WO2010033941A1
(en)
|
2008-09-22 |
2010-03-25 |
Array Biopharma Inc. |
Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
|
|
NZ779754A
(en)
|
2009-01-16 |
2023-04-28 |
Exelixis Inc |
Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
|
|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
|
ME03376B
(me)
|
2010-05-20 |
2020-01-20 |
Array Biopharma Inc |
Makrociklička jedinjenja kао inhibiтori trk kinaze
|
|
MX352926B
(es)
|
2010-09-27 |
2017-12-14 |
Exelixis Inc |
Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis osteoblasticas en los huesos.
|
|
BR112013020362A2
(pt)
|
2011-02-10 |
2018-05-29 |
Exelixis Inc |
processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem
|
|
EP2758057B1
(en)
|
2011-09-22 |
2017-05-31 |
Exelixis, Inc. |
Method for treating osteoporosis
|
|
CN104395284A
(zh)
|
2011-10-20 |
2015-03-04 |
埃克塞里艾克西斯公司 |
制备喹啉衍生物的方法
|
|
WO2013166296A1
(en)
|
2012-05-02 |
2013-11-07 |
Exelixis, Inc. |
A dual met - vegf modulator for treating osteolytic bone metastases
|
|
JP6513567B2
(ja)
*
|
2012-09-07 |
2019-05-15 |
エクセリクシス， インク． |
肺腺癌の治療で使用するためのｍｅｔ、ｖｅｇｆｒ、およびｒｅｔの阻害剤
|
|
CA2907334C
(en)
*
|
2013-03-15 |
2021-12-07 |
Exelixis, Inc. |
Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
|
|
US11564915B2
(en)
|
2013-04-04 |
2023-01-31 |
Exelixis, Inc. |
Cabozantinib dosage form and use in the treatment of cancer
|
|
BR112016018450A2
(pt)
|
2014-02-14 |
2018-09-18 |
Exelixis Inc |
formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso
|
|
EP3119476A1
(en)
|
2014-03-17 |
2017-01-25 |
Exelixis, Inc. |
Dosing of cabozantinib formulations
|
|
US20170044621A1
(en)
*
|
2014-04-18 |
2017-02-16 |
Blueprint Medicines Corporation |
Met fusions
|
|
UA121655C2
(uk)
*
|
2014-04-25 |
2020-07-10 |
Екселіксіс, Інк. |
Спосіб лікування аденокарциноми легень
|
|
CN104788372B
(zh)
*
|
2014-07-25 |
2018-01-30 |
上海圣考医药科技有限公司 |
一种氘代卡博替尼衍生物、其制备方法、应用及其中间体
|
|
EP3174854B1
(en)
|
2014-07-31 |
2022-08-24 |
Exelixis, Inc. |
Method of preparing fluorine-18 labeled cabozantinib and its analogs
|
|
MX382904B
(es)
|
2014-08-05 |
2025-03-13 |
Exelixis Inc |
Combinaciones de fármacos para tratar mieloma múltiple.
|
|
CN113354649B
(zh)
|
2014-11-16 |
2024-12-10 |
阵列生物制药公司 |
一种新的晶型
|
|
WO2016127074A1
(en)
|
2015-02-06 |
2016-08-11 |
Blueprint Medicines Corporation |
2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
|
|
BR112018000808A2
(pt)
|
2015-07-16 |
2018-09-04 |
Array Biopharma Inc |
compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
|
|
EP3368039A1
(en)
|
2015-10-26 |
2018-09-05 |
The Regents of The University of Colorado, A Body Corporate |
Point mutations in trk inhibitor-resistant cancer and methods relating to the same
|
|
SI3371171T1
(sl)
|
2015-11-02 |
2024-03-29 |
Blueprint Medicines Corporation |
Inhibitorji ret
|
|
US10183928B2
(en)
|
2016-03-17 |
2019-01-22 |
Blueprint Medicines Corporation |
Inhibitors of RET
|
|
US10045991B2
(en)
|
2016-04-04 |
2018-08-14 |
Loxo Oncology, Inc. |
Methods of treating pediatric cancers
|
|
AU2017246547B2
(en)
|
2016-04-04 |
2023-02-23 |
Loxo Oncology, Inc. |
Methods of treating pediatric cancers
|
|
FI3439662T3
(fi)
|
2016-04-04 |
2024-09-04 |
Loxo Oncology Inc |
(s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin nesteformulaatioita
|
|
EP3442531A1
(en)
|
2016-04-15 |
2019-02-20 |
Exelixis, Inc. |
Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
|
|
EP3454886A1
(en)
|
2016-05-13 |
2019-03-20 |
Instituto de Medicina Molecular |
Methods of treating diseases associated with ilc3 cells
|
|
EP3458456B1
(en)
|
2016-05-18 |
2020-11-25 |
Loxo Oncology Inc. |
Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
|
|
US10227329B2
(en)
|
2016-07-22 |
2019-03-12 |
Blueprint Medicines Corporation |
Compounds useful for treating disorders related to RET
|
|
WO2018022761A1
(en)
|
2016-07-27 |
2018-02-01 |
Blueprint Medicines Corporation |
Substituted cyclopentane-amides for treating disorders related to ret
|
|
TWI704148B
(zh)
|
2016-10-10 |
2020-09-11 |
美商亞雷生物製藥股份有限公司 |
作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
|
|
TWI752098B
(zh)
|
2016-10-10 |
2022-01-11 |
美商亞雷生物製藥股份有限公司 |
作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
|
|
JOP20190092A1
(ar)
|
2016-10-26 |
2019-04-25 |
Array Biopharma Inc |
عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
|
|
WO2018136661A1
(en)
|
2017-01-18 |
2018-07-26 |
Andrews Steven W |
SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
|
|
WO2018136663A1
(en)
|
2017-01-18 |
2018-07-26 |
Array Biopharma, Inc. |
Ret inhibitors
|
|
JOP20190213A1
(ar)
|
2017-03-16 |
2019-09-16 |
Array Biopharma Inc |
مركبات حلقية ضخمة كمثبطات لكيناز ros1
|
|
EP3674325A4
(en)
|
2017-08-21 |
2021-11-03 |
Taiho Pharmaceutical Co., Ltd. |
FUSION PROTEIN OF DCTN1 PROTEIN WITH RET PROTEIN
|
|
TWI791053B
(zh)
|
2017-10-10 |
2023-02-01 |
美商亞雷生物製藥股份有限公司 |
6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
|
|
TWI876442B
(zh)
|
2017-10-10 |
2025-03-11 |
美商絡速藥業公司 |
6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
|
|
EP3740490A1
(en)
|
2018-01-18 |
2020-11-25 |
Array Biopharma, Inc. |
Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
|
|
US11472802B2
(en)
|
2018-01-18 |
2022-10-18 |
Array Biopharma Inc. |
Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
|
|
JP7060694B2
(ja)
|
2018-01-18 |
2022-04-26 |
アレイ バイオファーマ インコーポレイテッド |
Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物
|
|
CN117402114A
(zh)
|
2018-01-26 |
2024-01-16 |
埃克塞里艾克西斯公司 |
用于治疗激酶依赖性病症的化合物
|
|
PE20210096A1
(es)
|
2018-04-03 |
2021-01-12 |
Blueprint Medicines Corp |
Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret
|
|
TWI831259B
(zh)
|
2018-06-15 |
2024-02-01 |
漢達生技醫藥股份有限公司 |
包含達沙替尼十二烷基硫酸鹽組合物的膠囊
|
|
CN110862397A
(zh)
*
|
2018-08-27 |
2020-03-06 |
北京赛特明强医药科技有限公司 |
二噁烷并喹唑啉与二噁烷并喹啉类化合物及其制备方法与应用
|
|
CN112996794A
(zh)
|
2018-09-10 |
2021-06-18 |
阿雷生物药品公司 |
作为ret激酶抑制剂的稠合杂环化合物
|
|
EP4157829A1
(en)
|
2020-05-29 |
2023-04-05 |
Blueprint Medicines Corporation |
Solid forms of pralsetinib
|
|
DE102020005002A1
(de)
*
|
2020-08-17 |
2022-02-17 |
Epo Experimentelle Pharmakologie & Onkologie Berlin-Buch Gmbh |
Mittel zur Therapie von Tumorerkrankungen
|
|
EP4347645A1
(en)
|
2021-06-03 |
2024-04-10 |
Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud Foundation |
Neuro-mesenchyme units control ilc2 and obesity via a brain-adipose circuit
|
|
CN114354789B
(zh)
*
|
2021-12-27 |
2023-08-29 |
深圳海王医药科技研究院有限公司 |
一种同时测定卡博替尼类似物及其有关物质的方法
|
|
WO2023230770A1
(en)
*
|
2022-05-30 |
2023-12-07 |
Suzhou Singleron Biotechnologies Co., Ltd. |
Methods of lung adenocarcinoma treatment with non anti-luad drugs or compounds
|
|
WO2024163400A1
(en)
|
2023-01-31 |
2024-08-08 |
Handa Oncology, Llc |
Improved cabozantinib compositions and methods of use
|